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ABSTRACT
Objectives: To value health resource utilisation and
productivity losses in DESIR, a longitudinal French
cohort of 708 patients with early spondyloarthritis
(SpA) enrolled between 2007 and 2010, and identify
factors associated with costs in the first 3 years of
follow-up.
Methods: Self-reported clinical data from DESIR and
French public data were used to value health resource
utilisation and productivity losses in 2013 Euros.
Factors associated with costs, including and excluding
biological drugs, were identified in generalised linear
models using the generalised estimating equations
algorithm to account for repeated observations over
participants.
Results: The mean (±SD) annual cost per patient was
€5004±6870 in year 1, decreasing to €4961±7457 in
year 3. Patients who never received a biologic had
mean 3-year total costs of €4789±6022 compared to
€38 206±19 829 among those who received a biologic.
Factors associated with increased total costs were
peripheral arthritis (rate ratio (RR) 1.19; 95% CI 1.04
to 1.37; p<0.0001), time on biologics (RR 1.23 per
month; 1.21, 1.24; p<0.0001), and average BASFI
score (RR 1.18/10 point increase; 1.15, 1.25;
p<0.0001). Factors associated with increased costs
excluding biologics were baseline age (RR 1.10 per
5 year increase; 1.05, 1.16; p<0.0001), peripheral
arthritis (RR 1.20; 1.02, 1.40; p<0.0133), time on
biologics (RR 1.04 per month; 1.02, 1.05; p<0.0001),
and average BASDAI score (RR 1.21 per 10 point
increase; 1.16, 1.25; p<0.0001).
Conclusions: In addition to biologics, factors like age,
peripheral arthritis and disease activity independently
increase SpA-related costs. This study may serve as a
benchmark for cost of illness among patients with
early SpA in the biologic era.
INTRODUCTION
Spondyloarthritis (SpA) is a family of chronic
rheumatic diseases that includes ankylosing
spondylitis (AS), psoriatic spondyloarthritis
(PsA), reactive SpA, SpA with inﬂammatory
bowel disease and undifferentiated SpA.1 In
its early phases, SpA is often undifferenti-
ated, and corresponds to the concept of
inﬂammatory back pain (IBP), the key
feature of the disease.2 To date, most eco-
nomic studies of SpA have examined out-
comes among patients with AS or PsA
speciﬁcally, and have not included patients
with other SpA subtypes or with early SpA
symptoms that are still evolving. A severe
form of SpA, AS has been shown to cause sig-
niﬁcant pain, functional disability and loss of
mobility3 In turn, these physical outcomes
are associated with substantial health
resource utilisation and work productivity
loss among patients with AS.4 5
Key messages
What is already known about this subject?
▸ Spondyloarthritis leads to healthcare costs as
well as productivity loss, the latter having been
shown to be the most significant cost driver.
However, there is a lack of cost-of-illness
studies among patients with early SpA in the
biologics era.
What does this study add?
▸ In the biologic era, medication is the greatest
cost driver among patients with SpA, exceeding
productivity loss. Other factors like age, periph-
eral arthritis and functional ability are independ-
ently associated with total costs. In a cohort of
patients with early SpA using biologics for less
than 3 years, biologic use was associated with
increased costs outside of biologics.
How might this impact on clinical practice?
▸ This study identifies factors associated with
SpA-related costs in the biologic era, potentially
pointing towards priority areas for biologics use
and providing a new benchmark for cost of
illness among patients with early SpA.
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In 2012, a systematic review identiﬁed 15 economic
studies of SpA conducted worldwide since 2002, nine of
which evaluated health resource utilisation and work
productivity loss. The median cost of health resource
utilisation in 2012 US dollars was $3764 per patient per
year, compared to a median cost of productivity loss of
$4999.6 More recently, biological TNF blockers have
been made available for the treatment of moderate to
severe SpA, increasing the cost of illness compared to
previous years in which non-steroidal anti-inﬂammatory
drugs (NSAIDs) were the only available drug therapy.7
The objective of this study was to value health resource
utilisation and productivity losses among patients in the
DESIR cohort,8 a longitudinal, multicentre study of early
SpA in France. We further aimed to determine factors
associated with total costs and with costs excluding biolo-
gics (‘non-biologic costs’) among DESIR patients.
METHODS
Participants
The DESIR cohort9 includes 708 patients aged 18–50
with early IBP lasting more than 3 months but less than
3 years, and suggestive of SpA according to the rheuma-
tologists’ assessment (score ≥5 on a 0–10 Numerical
Rating Scale where 0=not suggestive and 10=very suggest-
ive). Patients were required to fulﬁl the Calin10 or
Berlin11 IBP criteria. Patients with a deﬁnitive diagnosis
of non-SpA back pain, a history of previous biological
TNF-blocker use, or conditions that could affect
informed consent and/or compliance (eg, alcoholism,
psychiatric disorders) were excluded. All patients
attended their baseline study visit between October 2007
and May 2010. Follow-up visits collecting self-report
questionnaire data occurred every 6 months in the ﬁrst
2 years and every year thereafter, and covered the health
resource use since the previous visit. Our analyses
included the ﬁrst 3 years of follow-up, that is, baseline
plus follow-up visits at months 6, 12, 18, 24, 36. Data up
to month 12 were from the DESIR database locked in
February 2014, and data from months 18 to 36 from that
locked in April 2015.
Costing methods
Our analysis estimated the total cost from the societal
perspective (all payers combined) of all-cause health
resource utilisation, speciﬁcally health practitioner visits,
hospitalisations (including emergency room visits and
surgeries), medical workups, and medications), and
work productivity losses. Although we aimed to include
as many societal costs as possible, other patient
out-of-pocket costs (eg, transportation, devices, caregiver
expenses and other costs sometimes termed ‘non-
medical’) were not included.
Valuing health resource use
Detailed costing methods are described in online
supplementary tables S1–S4. Unit costs for health
practitioner visits were estimated by adding base tariffs
from the French National Health Insurance12 to the
average cost of extra billings based on data from the
IRDES (Institut de Recherche et de Documentation en
Economie de la Santé)13 Eco-Santé database.14 Data on
medical workups included laboratory analyses on blood
and urine and functional/diagnostic tests. On the basis
of clinical expertise, the cost of blood tests was estimated
assuming the following standard laboratory analyses
among patients with SpA: erythrocyte sedimentation rate
(ESR); C-reactive protein (CRP); haemogram including
platelets; thrombocytes; transaminases; creatinine; and
creatinine clearance. Blood collection was valued at
15 min of nurse care; the unit cost of blood tests was the
cost of analysis plus the cost of collection as per the
French public insurance fee schedule. Urine tests were
assumed to include urine protein only and no collection
fee was applied. The following tests were attributed a
single standard cost: mammography, MRI, bone densi-
tometry, scintigraphy, respirometry, colonoscopy and
ﬁbroscopy. For X-rays, ultrasounds, scans and ‘other
exams’, free-text data were reviewed individually and
assigned speciﬁc examination codes which were linked
to unit costs.
Data on medications included NSAIDs, DMARDs
(conventional synthetic—csDMARDs—or biologic—
bDMARD), corticosteroids (oral, intramuscular,
intra-articular and intravenous) and analgesics. For aba-
tacept, inﬂiximab and certolizumab, prices per milli-
gram were derived from list prices in France using the
Vidal dictionary.15 For all other drugs, cost data from the
French public drug program16 were used to derive a
price per milligram for each drug. Drugs were valued by
multiplying price per milligram by number of milligrams
per day by number of days of use (except injectable cor-
ticoids, which were valued by multiplying price per milli-
gram by number of milligrams in the reported number
of injections). Where dose data were missing, standard
dosages were imputed taking into account the patient’s
weight where applicable. For inﬂiximab only, a standard
cost for administration in day hospital was applied every
6 weeks for the duration of the therapy.
Data on hospitalisations were assigned a diagnosis or
act code and linked to Diagnosis-Related Group (DRG)
codes using 2012 data from the French national agency
for hospital information (ATIH, ‘Agence Technique de
l’Information sur l’Hospitalisation’).17 Selected DRG
were then linked to costs using 2012 ATIH data.18 The
base-case analysis used the 6-digit DRG selected as the
best ﬁt; sensitivity analyses were performed using DRG
sharing the same ﬁrst ﬁve digits as the best-ﬁt DRG (see
online supplementary table S3). All unit costs were
adjusted to 2013 Euros based on the Consumer Price
Index19 and multiplied by frequency of use.
Valuing work productivity loss
Data on patients’ profession were collected in eight cat-
egories (table 1). Average daily wage data were obtained
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from the French Ministry of Agriculture20 and from the
French National Institute of Statistics and Economic
Studies (‘INSEE’).20 Productivity loss was valued by
multiplying the number of self-reported workdays lost
per period by the average daily wage by professional cat-
egory over the entire population of French workers as
estimated by these public data sources. The age and sex
distribution of the DESIR cohort was compared to that
of the population of French workers from which average
daily wages were obtained and wages were not further
adjusted for age and sex.
Handling missing clinical and cost data
Missing cost and clinical data were imputed using the
Monte Carlo Markov Chain (MCMC) multiple imput-
ation procedure, the last observation carried forward
(LOCF) method, probabilistic imputation, or with nega-
tive values based on clinical expertise. Speciﬁcally, for
clinical variables in which ﬂuctuations are normal and
commonly observed clinically (ie, ASDAS-CRP, BASDAI,
BASFI and HAQ), missing data were handled with
MCMC imputation, which was considered the best strat-
egy for representing this variability. For clinical variables
observed to have greater stability, either the LOCF
method or probabilistic imputation was used in lieu of
MCMC imputation, as these methods provide better
control over the variability of values imputed; LOCF was
used if all patients had baseline data, while probabilistic
imputation was used if baseline data were missing. The
imputation model is described in detail in the online
supplementary appendix.
Statistical analyses
Patient characteristics were described by the mean±SD
or number (%) at baseline. For descriptive purposes,
patients were divided into four subsets based on imaging
status: X-ray damage only; MRI inﬂammation only;
X-Ray damage and MRI inﬂammation; neither. Costs of
health resource utilisation and productivity losses were
expressed as yearly costs. For health resource utilisation,
year 1 costs were the sum of costs reported at months 6
and 12; year 2 costs were the sum of costs reported at
months 18 and 24; year 3 costs were those reported at
month 36. For productivity losses, yearly costs were those
reported at the 12-month, 24-month and 36-month
visits. Yearly costs were described by the median and
mean±SD.
To describe factors associated with annual total costs
and non-biologic costs over the 3 years, we used general-
ised linear models with a γ distribution of log link and a
generalised estimating equations algorithm to account
for repeated measures within participants. The inde-
pendent variables year, baseline age and sex were
chosen to be included in all models throughout develop-
ment. Other independent variables of interest included
baseline education; profession; presence of peripheral
arthritis at baseline; DESIR study centre; number of
months on biologics; baseline imaging status; baseline
BASDAI and BASFI values; and mean BASDAI and
BASFI values (where year 1 mean=mean of months 0, 6,
12; year 2 mean=mean of months 12, 18, 24; and year 3
mean=mean of months 24, 36). At the outset, baseline
and mean BASDAI and BASFI values were tested for col-
linearity and examined alone and together in models.
Goodness of ﬁt assessed by the quasi-likelihood statistic
(QIC) was used to compare the model ﬁt among
models with various BASDAI and BASFI values (base-
line, mean, or baseline and mean together).21–23 The
model with the best ﬁt was chosen for inclusion in subse-
quent models. All other independent variables of inter-
est were examined separately in models adjusting for
year, age and sex, and variables associated with the
outcome at p<0.20 were selected for inclusion in subse-
quent models. Model selection was then done in a
Table 1 Baseline characteristics of the DESIR cohort
All (n=708)
Count
Per
cent
Age, sex, ethnicity
Age group <25 133 18.8
Age group ≥25 and <55 572 80.1
Age group ≥50 3 0.4
Male 327 46.2
Caucasian 634 89.6
Highest level of education
High school or less 286 40.4
Post-secondary school 418 59
Profession*
Agriculturer 6 0.9
Artisan, retailer or small business
owner
35 4.9
Executive or academic 151 21.3
Intermediate professional 54 7.7
Employee 299 42.6
Tradesperson 64 9
Without professional occupation 93 13.3
Clinical characteristics
Early onset (<17 years) 13 1.8
Late onset (>44 years) 72 10.2
Presence of extra-articular
manifestations
188 26.6
Uveitis 60 8.5
Psoriasis 112 15.8
Crohn’s disease 18 2.5
HLA B27 positive 410 57.9
ASAS criteria (total): positive 486 68.6
ASAS clinical criteria: positive 404 57.1
ASAS imaging criteria: positive 286 40.4
Clinical values Mean SD
Disease duration in years 1.5 0.9
Physician’s assessment of disease
activity (0–10)
4.3 2.2
BASDAI score (0–100) 44.7 20
BASFI score (0–100) 30.4 22.8
*Per cent values do not total 100 due to missing baseline data.
ASAS, the Assessment of SpondyloArthritis international Society.
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backward stepwise manner, beginning with all variables
and removing those that were not associated with the
outcome at p<0.05 to increase goodness of ﬁt based on
the QIC. All analyses were performed using SAS 9.4.
RESULTS
Patient characteristics
At baseline, the mean age of patients was 33.7±8.6 years
and mean disease duration was 1.5±0.8 years. Just under
half of the patients were male (46.2%) and the majority
were Caucasian (89.6%) (table 1). Most patients were
HLA-B27-positive (57.9%). The mean BASDAI score (on
100) at baseline was 44.7±20.0 and the mean BASFI
score was 30.5±22.8. The most common extrarheumato-
logical manifestations were psoriasis (15.8%) and uveitis
(8.5%). At baseline, 286 patients satisﬁed the
Assessment of SpondyloArthritis international Society
(ASAS imaging criteria (40.4%) and 404 the ASAS clin-
ical criteria (57.1%); 486 patients satisﬁed one or the
other (68.6%). Table 1 shows the characteristics of
patients by imaging status, that is, X-ray damage alone
(7.2%), MRI inﬂammation (13.8%); X-ray damage and
MRI inﬂammation (18.6%), neither (56.9%); a total of
24 patients had no data available to describe imaging
status. Attendance at follow-up visits declined over time:
of the 708 patients enrolled at baseline, 704 attended
the 6-month visit, 698 the 12-month visit, 691 the
18-month visit, 692 the 24-month visit, and 631 the
36-month visit.
Costs
Health resource utilisation
Table 2 shows the estimated costs of health resource util-
isation and productivity losses among all DESIR patients
over 3 years. Medication was the largest cost component
in all years, representing over 50% of all costs in all
years. The absolute mean cost of medication increased
from €2680.2±5339.6 in year 1 to €3339.2±6224.1 in year
2 to €3396.3±6476.5 in year 3. The proportion of
patients incurring costs from biologics was approxi-
mately a quarter each year. The cost of biologics
accounted for approximately 95% of medication costs
each year.
Health practitioner visits, the second largest cost com-
ponent of health resource utilisation in all years,
declined from €733.2±788.9 in year 1 to €615.0±783.4 in
year 2 and €481.0±676.2 in year 3. Hospitalisation costs
were incurred by a quarter to a ﬁfth of patients, repre-
senting under 10% of costs in each year. The mean hos-
pitalisation cost per patient was €498.4±1318.9 in year 1,
€526.2±1325.7 in year 2 and €423.3±1100.8 in year
3. Medical workups were consistently the smallest com-
ponent of health resource utilisation, never exceeding
5% of yearly costs.
Productivity losses
Approximately a third of patients (30.1%) incurred
productivity losses in year 1; this decreased to a quarter
of patients in year 2 (23.4%) and year 3 (24.4%). The
mean cost of productivity losses was €843.4±2899.1 in
Table 2 Cost components as proportion of total costs by year of follow-up and biologics use
Patient group Cost component Year 1 (%) Year 2 (%) Year 3 (%) Three-year total (%)
All patients (n=708) Health practitioners 15 11 10 12
Medical workups 5 4 3 4
Hospitalisations 10 10 9 9
Biologics 50 59 66 58
All drugs 54 61 68 61
Productivity loss 17 14 10 14
All costs excluding
biologics
50 41 34 42
Ever received a biologic (n=225) Health practitioners 8 7 5 7
Medical acts 4 2 2 3
Hospitalisations 6 5 3 5
Biologics 67 74 81 74
All drugs 69 75 82 76
Productivity loss 13 10 7 10
All costs excluding
biologics
33 26 19 26
Never received a biologic
(n=483)
Health practitioners 33 29 29 31
Medical acts 9 8 9 9
Hospitalisations 22 26 32 26
Biologics 0 0 0 0
All drugs 8 7 8 7
Productivity loss 28 29 22 27
All costs excluding
biologics
100 100 100 100
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year 1, €768.9±3368.0 and €497.0±1951.0 in year 3. In
year 1, productivity losses represented 16.8% of total
costs, compared to 14.1% of total costs in year 2 and
10.0% of total costs in year 3.
Total costs
The mean annual total cost per patient was €5004.1
±6870.2 in year 1, €5444.1±7936.9 in year 2 and €4960.6
±7457.4 in year 3. Mean annual total costs rose with bio-
logic use: patients who did not receive a biologic had
mean total costs of €1867.9±3056.6 in year 1, €1628.2
±3090.3 in year 2 and €1292.9±2059.6 in year 3, com-
pared to €11 736.4±7882.6 in year 1, €13 635.4±8915.1 in
year 2 and €12 833.9±8667.4 in year 3 among patients
who received a biologic. In all years, biologics repre-
sented over 50% of total costs, up to 66.3% in year
3. Overall, the mean 3-year total cost among patients was
€15 408.7±19 793.5. Patients who never received a bio-
logic had mean 3-year total costs of €4789.04±6021.8
compared to €38 205.74±19 829.3 among those who
received a biologic. The estimated total costs in the
cohort over 3 years amounted to €10 909 399.9±19 574.0.
Of this, patients who received a biologic accounted for
an estimated €8 596 291.6±4860.9 or 78.8% of all costs in
the cohort. Figure 1 compares the trends in costs over
the study period overall and for patients who received
and did not receive a biologic.
Factors associated with costs
Total costs
In the ﬁnal model (table 3), each month of biologics
use was associated with a 23% increase (rate ratio (RR):
1.23; 95% CI 1.21 to 1.24) in total costs. The presence
of peripheral arthritis at baseline was associated with a
19% increase (RR: 1.19; 95% CI 1.04 to 1.37) in total
costs, while every 10-point increase in the average BASFI
score was associated with an 18% increase in total costs
(RR: 1.18; 95% CI 1.15 to 1.22). Although absolute costs
were higher in year 2 than year 1 (table 4), when
adjusting for time on biologics, costs in years 2 and 3
were signiﬁcantly lower than in year 1 (table 3). Imaging
status was not signiﬁcantly associated with total costs and
was excluded from the ﬁnal model (ﬁgure 2).
Cost excluding biologics
In the ﬁnal model (table 3), each month of biologics
use was associated with a 4% increase (RR: 1.04; 95% CI
1.02 to 1.05) in non-biologic costs. The presence of per-
ipheral arthritis at baseline was associated with a 20%
increase (RR: 1.20; 95% CI 1.02, 1.40) in non-biologics
costs; every 10-point increase in the average BASDAI
score was associated with a 21% increase in non-biologic
costs (RR: 1.21; 95% CI 1.16 to 1.25). Every 5-year
increase in age was associated with a 10% increase (RR:
1.10; 95% CI 1.05 to 1.16) in non-biologic costs, while
males had 31% less costs relative to females (RR: 0.69;
95% 0.58 to 0.81). Imaging status was not signiﬁcantly
associated with costs excluding biologics and was
excluded from the ﬁnal model.
DISCUSSION
This study described costs related to health resource util-
isation and work productivity losses among patients with
early SpA over 3 years. Our ﬁndings reﬂect the cost
impact of biologics, which represented by far the largest
cost component among DESIR patients. In the prebiolo-
gic era among patients with AS, work productivity loss
was observed to account for the majority of total costs,
for example, from 62% of total annual costs among
patients with AS in Hong Kong24 to 74% of total annual
costs among patients with AS in the UK.25 In our study,
an analysis of patients with early SpA in the biologic era,
productivity loss may be expected to represent a lower
proportion of costs given patients’ better functional
status and higher drug costs; that said, productivity loss
costs among DESIR patients still represented between
10% and 17% of annual costs over the study period. In
terms of absolute costs, work productivity loss costs
among DESIR patients (which ranged from €843 in year
one to €497 in year 3) are consistent with those in a
Dutch cohort of patients with early SpA (approximately
€422 over 1 year).26 We note that our estimates of prod-
uctivity loss costs are conservative: we did not calculate
the costs of presenteeism, that is, the cost of reduced
performance at work, which is another potentially
important source of costs.27
Currently, there is increased interest in non-
radiographic axial SpA, deﬁned as SpA in the absence
of deﬁnite sacroiliac changes on X-ray, which includes
both patients who satisfy only the clinical criteria for
SpA and those with active inﬂammation in the sacroiliac
joints visible only on MRI.28 To the best of our knowl-
edge, this is the ﬁrst longitudinal study of patients with
SpA that has explored the impact of radiographic
damage on cost, distinguishing between damage on
X-Ray with or without MRI inﬂammation. Interestingly,Figure 1 Yearly costs among biologics users.
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Table 3 Models of total cost and non-biologic costs
Outcome Variable
Rate ratio (95%
CI) p Value Estimate SE
Estimate
lower
bound
Estimate
upper
bound
Min.
estimate
Max.
estimate
Minimum
rate ratio
Maximum
rate ratio
Total costs Age at baseline
(every 5-year
increase)
1.06 (1.02 to 1.11) 0.006 0.060 0.022 0.017 0.102 0.055 0.065 1.06 1.07
Male vs female 0.75 (0.65 to 0.87) 0.000 −0.287 0.074 −0.432 −0.142 −0.304 −0.265 0.74 0.77
Time on biologics
(in months)
1.23 (1.21 to 1.24) <0.0001 0.205 0.005 0.195 0.216 0.205 0.205 1.23 1.23
Year 2 vs year 1 0.89 (0.78 to 1.01) 0.063 −0.119 0.064 −0.244 0.007 −0.125 −0.114 0.88 0.89
Year 3 vs year 1 0.71 (0.63 to 0.81) <0.0001 −0.339 0.062 −0.462 −0.217 −0.367 −0.321 0.69 0.73
Average BASFI
score (every
10-point increase)
1.18 (1.15 to 1.22) <0.0001 0.168 0.015 0.137 0.198 0.164 0.172 1.18 1.19
Presence of
peripheral arthritis
at baseline
1.19 (1.04 to 1.37) 0.014 0.177 0.072 0.036 0.318 0.166 0.198 1.18 1.22
Non-biologic
costs
Age at baseline
(every 5-year
increase)
1.10 (1.05 to 1.16) 0.000 0.097 0.025 0.047 0.147 0.092 0.104 1.10 1.11
Male vs female 0.69 (0.58 to 0.81) <0.0001 −0.377 0.087 −0.548 −0.206 −0.398 −0.349 0.67 0.71
Time on biologics
(in months)
1.04 (1.02 to 1.05) <0.0001 0.037 0.008 0.022 0.052 0.037 0.038 1.04 1.04
Year 2 vs year 1 0.87 (0.75 to 1.00) 0.050 −0.143 0.073 −0.286 0.000 −0.151 −0.139 0.86 0.87
Year 3 vs year 1 0.72 (0.63 to 0.83) <0.0001 −0.327 0.072 −0.470 −0.184 −0.357 −0.301 0.70 0.74
Average BASDAI
score (every
10-point increase)
1.21 (1.16 to 1.25) <0.0001 0.187 0.019 0.151 0.224 0.185 0.192 1.20 1.21
Presence of
peripheral arthritis
at baseline
1.20 (1.02 to 1.40) 0.024 0.181 0.080 0.024 0.338 0.170 0.198 1.18 1.22
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Table 4 Health resource use and productivity loss costs in 2013 Euros by year of follow-up and biologics use
Year 1 Year 2 Year 3 Three-year total
Patient group
Resource
component
% patients
with costs Mean SD Med
% patients
with costs Mean SD Med
% patients
with costs Mean SD Med
% patients
with costs Mean SD Med
All patients
(n=708)
Health
practitioners*
91 733 789 486 84 615 783 350 77 481 676 254 97 1829 1860 1239
Medical
workups†
79 249 306 144 71 195 257 85 66 163 234 65 92 607 618 403
Biologics 24 2515 5322 0 27 3205 6202 0 26 3287 6460 0 32 9007 16 512 0
All drugs 100 2680 5340 155 100 3339 6224 127 100 3396 6477 99 100 9416 16 565 408
HRU costs 100 4161 5901 1297 100 4675 6780 1107 100 4464 6859 856 100 13 299 17 770 4505
Productivity loss 30 843 2899 0 23 769 3368 0 24 497 1951 0 46 2109 5846 0
All costs
excluding
biologics
100 2489 3629 1228 100 2239 4159 872 100 1673 2718 706 100 6402 7770 3708
All costs 100 5004 6870 1547 100 5444 7937 1287 100 4961 7457 1063 100 15 409 19 794 5358
Ever received
a biologic
(n=225)
Health
practitioners*
99 997 886 722 94 909 922 577 86 702 886 399 100 2608 2175 1952
Medical
workups†
96 427 374 324 91 328 303 245 83 265 296 168 100 1020 716 922
Biologics 76 7913 6819 8510 86 10 084 7191 12 047 81 10 344 7641 12 694 100 28 341 17 606 28 554
All drugs 100 8123 6802 8548 100 10 265 7183 12 186 100 10 477 7650 12 716 100 28 865 17 568 28 962
HRU costs 100 10 214 7073 11 175 100 12 244 7422 13 437 100 11 889 7895 13 577 100 34 347 17 833 36 107
Productivity loss 41 1523 3723 0 33 1391 4827 0 34 945 2900 0 59 3859 8071 485
All costs
excluding
biologics
100 3823 4341 2019 100 3552 5614 1677 100 2490 3635 1217 100 9865 9727 6701
All costs 100 11 736 7883 12 477 100 13 635 8915 13 880 100 12 834 8667 13 765 100 38 206 19 829 39 306
Never
received a
biologic
(n=483)
Health
practitioners*
88 610 707 352 80 478 668 211 72 378 522 177 95 1466 1566 937
Medical
workups†
70 166 225 81 62 132 205 41 59 116 180 41 88 414 452 270
Biologics 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
All drugs 100 145 223 99 100 113 143 75 100 98 145 53 100 355 423 252
HRU costs 100 1341 1662 750 100 1149 1619 510 100 1004 1518 429 100 3495 3501 2240
Productivity loss 25 527 2360 0 19 479 2355 0 20 288 1241 0 40 1294 4206 0
All costs
excluding
biologics
100 1868 3057 850 100 1628 3090 566 100 1293 2060 521 100 4789 6022 2633
All costs 100 1868 3057 850 100 1628 3090 566 100 1293 2060 521 100 4789 6022 2633
*Health practitioners include physicians and other allied health professionals (nurse, physiotherapist, osteopath, etc).
†Medical workups include blood and urine tests, X-ray, ultrasound, scanner, MRI, bone densitometry, scintigraphy, respirometry, colonoscopy, mammography and fibroscopy.
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while preventing progression to radiographic SpA
remains a high priority from the clinical perspective, we
found no signiﬁcant independent effect of imaging
status on total costs or costs excluding biologics.
In this study, the most signiﬁcant cost component was
biologic drugs, and patients who ever received a biologic
accounted for over 75% of total costs in the cohort.
While this was not surprising, the ﬁnding that approxi-
mately a quarter of DESIR patients had received a bio-
logic by the 6-month visit (biologics use at baseline was
not permitted9) was higher than anticipated, suggesting
that biologics use was already relatively common even
among patients with early SpA in 2010. Whether biolo-
gics provide good value for money is being explored in a
separate study, which considers the impact of biologics
on health-related quality of life. Our study also found
peripheral arthritis, age and functional ability to be
related to total costs, indicating subgroups where biologic
use may be prioritised. In this study, we found that, in
the ﬁrst 3 years, treatment with biologics leads to
increased costs in other health resource use domains,
not a reduction as is sometimes expected; follow-up is
needed to determine whether this trend holds over a
longer period.
This study has some limitations. The DESIR cohort
includes only patients with early SpA in France between
2007 and 2014; the results cannot necessarily be general-
ised to patients with SpA with more advanced disease or
in other settings at other times. Indeed, it is unknown
whether similarly high rates of biologic use exist among
patients with early SpA in other countries; another
recently established early SpA cohort (‘SPACE’) is
ongoing in the Netherlands,29 but to the best of our
knowledge the prevalence of biologics use in this cohort
has not as yet been reported. A recent Canadian study
of patients with SpA seen clinically between 2003 and
2014 found that 48% had been treated with a biologic,
yet the mean disease duration (8 years) was much
longer in this sample than in DESIR.30 Generalisable to
patients with early SpA in France, our ﬁndings will allow
for future comparisons with other cohorts of patients
with early SpA, as well as the observation of trends
within DESIR over time.
In terms of costing methods employed, we did not
include non-SpA-related drugs, transportation or pres-
enteeism, or include other patient out-of-pocket costs.
Attendance declined over time and data imputation was
required. Resource utilisation was self-reported and the
potential exists for either underreported or overreported
utilisation. In order to exclude the excess resource util-
isation associated with study participation, we excluded
the baseline visit from cost estimates. However, study par-
ticipation could have also resulted in underestimation of
resource utilisation following the baseline visit, if study
visits replaced normal resource utilisation but were not
reported as such. Finally, work productivity losses were
estimated using self-reported workdays lost (rather than
hours lost) and average daily wages by professional cat-
egory, estimated from the entire population of French
workers. We used profession-speciﬁc daily wages and did
not further adjust wages for age and sex, although there
are small differences in the age and sex distribution in
DESIR compared to the French working population
from which income data were derived (48% female and
77% aged 25–54 among French workers vs 54% female
and 81% aged 25–54 in DESIR31). By not adjusting for
the 6% higher proportion of females in DESIR, it could
be argued that we have slightly overvalued productivity
losses, as daily wages among females in France are lower
than among males; however, we note that wage inequal-
ity functions more generally to minimise the value of
productivity loss. Although our valuation method pro-
vides a good estimate of productivity losses, we acknow-
ledge that a greater level of accuracy could be achieved
with direct self-report data on wage and productivity
losses expressed in hourly terms. Despite these limita-
tions, our ﬁndings are consistent with another recent
description of patients with early SpA26 and reﬂect pat-
terns of health resource utilisation and work productivity
loss within one of the largest early SpA cohorts to date.
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